Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tradipitant - Vanda Pharmaceuticals

Drug Profile

Tradipitant - Vanda Pharmaceuticals

Alternative Names: LY-686017; VLY 686

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; National Institute on Alcohol Abuse and Alcoholism; Vanda Pharmaceuticals
  • Class Antipruritics; Anxiolytics; Chlorobenzenes; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Gastroparesis
  • Phase II Motion sickness; Pruritus
  • Discontinued Alcoholism; Social phobia

Most Recent Events

  • 21 Oct 2019 Vanda Pharmaceuticals initiates the phase III EPIONE 2 trial for Atopic dermatitis in USA
  • 30 Sep 2019 Vanda Pharmaceuticals completes enrolment in the phase III EPIONE 1 trial for Atopic dermatitis in USA
  • 31 Jul 2019 Vanda Pharmaceuticals plans a phase III trial in Motion Sickness in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top